Among adults with type 2 diabetes (T2D), is the use of sodium-glucose cotransporter 2 inhibitors (SGLT2Is) associated with higher risk of male external genital infection (MEGI) than glucagon-like peptide-1 receptor agonists (GLP-1RAs)? This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.